Cargando…

Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis

OBJECTIVE: To evaluate the treatment outcome of second line drugs used in directly observed treatment, short-course (DOTS)-Plus regimen under Revised National Tuberculosis Control Program (RNTCP). MATERIALS AND METHODS: A prospective, observational study was carried out on multidrug resistant tuberc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Kalpesh, Desai, Mira, Solanki, Rajesh, Dikshit, Ram Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008910/ https://www.ncbi.nlm.nih.gov/pubmed/24799815 http://dx.doi.org/10.4103/0976-500X.130062

Ejemplares similares

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai
por: Udwadia, Zarir F, et al.
Publicado: (2016)

Outcomes associated with standardized treatment regimens for extensively drug-resistant tuberculosis
por: Aggarwal, Anivita, et al.
Publicado: (2020)

Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment
por: Tierney, Dylan B., et al.
Publicado: (2014)

Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome
por: Prasad, Rajendra, et al.
Publicado: (2017)

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
por: Yao, Ge, et al.
Publicado: (2023)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
por: Wahid, Abdul, et al.
Publicado: (2022)

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
por: Grace, Angeline G, et al.
Publicado: (2019)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China
por: Xia, Hui, et al.
Publicado: (2020)

Treatment Outcomes Associated with Multidrug-resistant Tuberculosis
por: Gupta, Nitin, et al.
Publicado: (2018)

Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality
por: Mitnick, Carole D., et al.
Publicado: (2013)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens
por: Park, Hae-Young, et al.
Publicado: (2023)

Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience
por: Singh, Abhijeet, et al.
Publicado: (2019)

Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients’ data analysis for outcome and effectiveness of the current regimens
por: Eshetie, Setegn, et al.
Publicado: (2018)

Treatment outcomes for multidrug-resistant tuberculosis in Eastern Taiwan
por: Lin, Chih-Bin, et al.
Publicado: (2019)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen
por: Achar, Jay, et al.
Publicado: (2015)

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen
por: Lempens, Pauline, et al.
Publicado: (2020)

Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
por: Ahuja, Shama D., et al.
Publicado: (2012)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study
por: Soeroto, Arto Yuwono, et al.
Publicado: (2021)

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens
por: Budak, Maral, et al.
Publicado: (2023)

Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam
por: Ngoc, Nguyen Bao, et al.
Publicado: (2021)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)

At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States
por: Sinha, Pranay, et al.
Publicado: (2023)

Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru
por: Tierney, Dylan B., et al.
Publicado: (2016)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
por: Putra, Oki Nugraha, et al.
Publicado: (2021)

Correction: Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
por: Ahuja, Shama D., et al.
Publicado: (2012)

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial
por: Bouton, Tara C., et al.
Publicado: (2017)

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study
por: Yuen, Courtney M., et al.
Publicado: (2015)

Effectiveness and Safety of a Shorter Treatment Regimen in a Setting with a High Burden of Multidrug-Resistant Tuberculosis
por: Trubnikov, Aleksandr, et al.
Publicado: (2021)

Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies
por: Mahardani, Putu Nandika, et al.
Publicado: (2022)

Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019–2020
por: Avaliani, Teona, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9pf2vvc5da838ir7qohntoqm6n